BERTIS Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2014

Location

Gyeonggi-do South Korea

Primary Industry

Biotechnology

About

Based in Gyeonggi-do, South Korea, and founded in 2014, BERTIS Inc. operates as a proteomics technology company. In February 2024, BERTIS Inc. raised KRW 20 billion in pre-IPO funding from Korea Development Bank, Winvest Venture Capital, and DreamCIS. As of 2024, the company is led by its co-CEOs, Dong-young Noh and Seung-man Han. BERTIS develops and offers proteomics-based clinical solutions for various cancer diseases. The company provides ProteoID (proteome integrated determination), which is a proteomics platform, and MASTOCHECK, a breast cancer early diagnosis blood test. The company plans to use the funds raised in February 2024 to market early diagnostic blood test products, extend its analysis service area, and expand its international business.

Current Investors

Meritz Fire & Marine Insurance, Smilegate Investment, Premier Partners

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Bioinformatics, Oncology/Cancer Treatment

Website

www.bertis.com

Verticals

Artificial Intelligence

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.